Drive Commercial Success

Charting the path to patient access for cell and gene therapy

When patients are waiting for life-altering treatments, every milestone is critical. Precision applies demonstrated expertise from quantifying the burden of disease for narrow patient populations to demonstrating and communicating the economic and clinical value of cell and gene therapies, traversing the commercialization landscapes to improve or save patient lives.

70%+ of approved cell and gene therapies commercially launched

Man and woman in masks doing cell and gene therapy commercialization services

Evidence Solutions and Value Demonstration

Innovative and disruptive technologies like cell and gene therapies face distinct commercialization and access challenges, especially in quantifying value. We surmount these obstacles with credible and relevant evidence that answers the demands of stakeholders from payers to policymakers.

Burden of Illness, Treatment Patterns, and Cost of Care

By directly quantifying the previously unknown burden of disease and the corresponding impact of new cell and gene therapies, we turn the conversation to value.

Treatment pattern analyses
Cost of illness for uncoded rare disease
Cost of caregiver burden
Patient preference studies
Pediatric populations utility measure

Literature Review and Analysis

We utilize cutting-edge evidence synthesis techniques to prepare for complex and unprecedented coverage conversations and address evidence gaps associated with small patient populations and single-arm clinical trials.

Natural history data analysis for synthetic controls
Systematic literature reviews
Expert elicitation in rare disease
Network meta-analyses
Indirect treatment comparisons
Evidence synthesis trial design simulation

Economic Models

Sophisticated modeling methodologies enable us to precisely measure a therapy’s value even in an environment of small patient populations and unknown duration of effect.

Cost-effectiveness/cost-utility modeling
Budget impact for costly single treatments
Cost consequence models

HTA Engagement and Real-World Evidence

We drive positive payer and HTA appraisals for cell and gene therapy, developing pioneering methodologies and confirming them with real-world evidence.

Single therapy ICER review preparation
Early scientific meetings with HTAs
HTA dossiers
RWE duration-of-effect studies

Pricing and Access Strategy

Our global market access and pricing strategies target the value of cell and gene therapies—as identified by former access decision makers who clearly understand actuarial analyses, payer and policy-maker practices and the most effective levers for coverage and access.

Market Access Strategy

We assess the global market access landscape for cell and gene therapies, refining the unique value drivers, then targeting critical access stakeholders, region by region.

Market-specific access assessments
Duration-of-effect evidence strategies
Coverage challenge evaluations
Reimbursement strategies for single treatments
Stakeholder segmentation
Channel strategies for unique distribution
Value end-point assessments

Patient Access Schemes and Innovative Payment Models

Knowing cost sensitivity carries implications for the uptake and appropriate use of cell and gene therapies, we devise innovative payment mechanisms that maximize availably for patients.

Fund flow analysis
Contracting stakeholder analysis
Single-treatment payment approaches

Distribution Strategies

Cell and gene therapy commercialization and distribution are highly nuanced, and many steps influence access. Critically, patients need support throughout the treatment process; our targeted strategies ensure they receive it.

HUB services strategies for coverage requirements
Selection of cell and gene therapy-experienced partners
Patient support SOP development

Cell and gene therapy commercialization team working virtually

Engagement Solutions for Cell and Gene Therapies

In the uncharted territory of cell and gene therapy, concise and effective communications are essential to reshape the minds of payers, providers, and patients. Our multidisciplinary engagement teams of scientists, former payers and marketing and investor relations specialists deliver.

Scientific Communications

As authorities in understanding and translating the science of medicine, we develop consistent, compelling scientific and medical communications that clarify the impact of innovative cell and gene therapy.

Scientific literature gap assessment
Scientific platform, narrative and lexicon
Core slide library
Publication planning and execution
Site training for cell therapies

Patient, Payer and Provider Engagement

We infuse your development program with engaged thought leadership, then ensure that key stakeholders have foundational evidence that drives home the value of your cell and gene therapy.

Center of Excellence and KOL mapping
Value propositions for undertreated diseases
Pre-approval information exchange
Healthcare Economic Information Exchange Communication
Field team training and technical manuals
HUB and patient support resources
Rare disease education
Cost and coverage guide
REMS training
Peer-to-peer programs

Brand Strategy and Promotion

Cell and gene therapies set new standards for care. Our commercialization services turn them into trusted treatments, integrating strategy, creativity, and technology into exceptional brand engagement platforms that change the minds of industry.

New standard-of-care brand strategy
Small-cohort patient identification and activation
Novel product-vision branding
Targeted digital programs (web, social)
Sales representative aids and tools
Congress booths and events

Investor Relations

We offer strategic, client-specific, investor-focused advisory services to cell and gene therapy companies across all market capitalizations and stages of development.

Messaging and positioning, including investment thesis development
Collateral material development: Corporate, quarterly earnings and scientific press release drafting, websites, corporate presentations, regulatory filings
Financing strategy and execution: Crossover financings, initial public offerings, SPACs, follow-on financings, M&A
Newsflow planning
Investor targeting and outreach
Sell-side engagement
Investor and industry events: KOL events, R&D days, analyst days, events around medical meetings, annual JP Morgan conference
Other: Perception studies, peer monitoring, corporate rebranding

Contact us